#AngioDynamics Latest
AngioDynamics has shown promising performance in its Q1 FY 2026 results, modestly exceeding analysts' expectations on revenue and adjusted metrics with 12% revenue growth. The company returned to adjusted EBITDA profitability of $2.2 million, compared to a loss in the prior year period, fueled by strong sales in its Med Tech segment, which grew 26.1% year-over-year, led by Auryon (up 20.1%), Mechanical Thrombectomy (up 41.2%), and NanoKnife (up 26.7%).
Management has raised its FY 2026 guidance for net sales, Med Tech segment growth, adjusted EBITDA, and adjusted EPS, acknowledging the upward momentum. The company reported a GAAP net loss of $0.26 per share for the quarter, highlighting the continued path to profitability.
Key drivers for future growth include scaling the NanoKnife platform for prostate tissue ablation, particularly for prostate cancer treatment and sustaining demand for its Auryon and thrombectomy tools. Recent results from the PRESERVE study published in European Urology showed 84% of men were free from in-field, clinically significant disease at 12 months, with quality-of-life outcomes largely preserved.
The platform recently received FDA 510(k) clearance, and its commercial success will depend on reimbursement coverage and clinical adoption.
#What Investors Need to Know About AngioDynamics
The company achieved 12% revenue growth in Q1 FY 2026.
Adjusted EBITDA profitability was restored.
There is strong momentum in the Med Tech segment, including thrombectomy, Auryon, and NanoKnife.
Management has increased guidance for full-year revenue and EBITDA.
Analysts see the stock as undervalued but are cautious due to execution risks.
#AngioDynamics At A Glance
AngioDynamics is a medical technology company specializing in innovative solutions for the treatment of vascular disease and surgical oncology. Its product line includes advanced devices for peripheral vascular disease, oncology therapies, and irreversible electroporation via the NanoKnife system, making it a significant player in the healthcare industry.
#Competitive Landscape
AngioDynamics competes with notable companies such as Boston Scientific, Medtronic, and Edwards Lifesciences. Each of these companies also operates within the medical technology field, which is characterized by rapid innovations and intense competition.
#Near-Term Catalysts and Risks
AngioDynamics is positioned for growth, driven by its solid product offerings and market demand. However, the company faces risks such as ongoing GAAP losses, competitive pressures, and the need to effectively scale its NanoKnife platform. Other challenges include cash burn management, securing reimbursement pathways, and achieving broad clinician adoption for its newer technologies. Managing these factors will be crucial for its sustained success in the upcoming quarters.
#Trading ANGO Stock
Investors considering AngioDynamics stock should frame their trades around the company's growth potential within the healthcare sector. With the stock being perceived as undervalued, it might be an attractive buy for those willing to bet on its recovery and growth trajectory. Understanding the company's focus on innovation and profitability can provide a strategic advantage in making informed investment decisions.
#FAQ
Why should I invest in a healthcare stock?
Investing in healthcare stocks can provide exposure to a dynamic industry characterized by consistent demand, particularly for companies delivering innovative solutions. Healthcare often remains resilient during economic downturns, making it a sector worth considering for long-term growth.
What are the risks associated with investing in AngioDynamics?
Investors should consider risks such as competition from major players, ongoing GAAP losses, and the company's execution in scaling its products.
How do I evaluate the growth potential of a healthcare company?
Look for indicators such as revenue growth, profitability, market demand for products, and management's guidance on future performance when evaluating a healthcare company's growth potential.
What financial metrics should I consider for healthcare stocks?
Key metrics include revenue growth rate, EBITDA margin, net profit margin, and market share, which can offer insights into a company's operational success and competitive positioning.